Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

FDA approves Roche’s Actemra COVID-19 trial

FDA approves Roche’s Actemra COVID-19 trial

It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with ... T cell therapies for cancer.

Latest news

More from news
Approximately 3 fully matching, plus 84 partially matching documents found.

Latest Intelligence

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of

  • The dawn of a new era in medical education The dawn of a new era in medical education

    Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies. ... therapies, where the administration is not as simple as

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics